2177-PUB: Improved Time-in-Range and Glycemic Variability in Adults with Type 1 Diabetes: An Analysis of 12-Week Flash Glucose Monitoring Data from a Multicenter Prospective Trial

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 2177-PUB
Author(s):  
LIXIN GUO ◽  
MEI ZHANG ◽  
HONGYU KUANG ◽  
YUXIU LI ◽  
XINHUA XIAO ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Prospective Trial ◽  
Glucose Monitoring ◽  
Glycemic Variability ◽  
Monitoring Data ◽  
Flash Glucose Monitoring ◽  
Time In Range

Frequency of flash glucose monitoring readings, hemoglobin A1c and time in range: a real life study in adults with type 1 diabetes

2020 ◽  
Vol 57 (11) ◽  
pp. 1395-1397 ◽  
Author(s):  
Andrea Laurenzi ◽  
Amelia Caretto ◽  
Mariluce Barrasso ◽  
Andrea Mario Bolla ◽  
Nicoletta Dozio ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Hemoglobin A1c ◽  
Real Life ◽  
Glucose Monitoring ◽  
Flash Glucose Monitoring ◽  
Life Study ◽  
Time In Range ◽  
Real Life Study

scholarly journals Achieving the HbA1c Target Requires Longer Time in Range in Pregnant Women with Type 1 Diabetes

2021 ◽  
Author(s):  
Ping Ling ◽  
Daizhi Yang ◽  
Nan Gu ◽  
Xinhua Xiao ◽  
Jing Lu ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Pregnant Women ◽  
Glucose Monitoring ◽  
Glycemic Variability ◽  
Pregnancy And Postpartum ◽  
Best Fitting ◽  
Time In Range ◽  
Hba1c Target ◽  
Mean Glucose

Abstract Aims Continuous glucose monitoring (CGM) overcomes the limitations of glycated hemoglobin (HbA1c). This study was to investigate the relationship between CGM metrics and laboratory HbA1c in pregnant women with type 1 diabetes. Methods An observational study enrolled pregnant women with type 1 diabetes who wore CGM devices during pregnancy and postpartum from 11 hospitals in China from January 2015 to June 2019. CGM data were collected to calculate time-in-range (TIR), time above range (TAR), time below range (TBR), and glycemic variability parameters. Relationships between the CGM metrics and HbA1c were explored. Linear and curvilinear regressions were conducted to investigate the best-fitting model to clarify the influence of HbA1c on the TIR-HbA1c relationship during pregnancy. Results A total of 272 CGM data and corresponding HbA1c from 98 pregnant women with type 1 diabetes and their clinical characteristics were analyzed in this study. Mean HbA1c and TIR were 6.49±1.29% and 76.16±17.97% during pregnancy, respectively. HbA1c was moderately correlated with TIR 3.5-7.8(R= -0.429, P=0.001), mean glucose (R= 0.405, P=0.001) and TAR 7.8 (R=0.435, P=0.001), but was weakly correlated with TBR 3.5 (R=0.034, P=0.001) during pregnancy. On average, a 1% (11 mmol/mol) decrease in HbA1c corresponded to an 8.5% increase in TIR 3.5-7.8. During pregnancy, HbA1c of 6.0%, 6.5% and 7.0% were equivalent to a TIR 3.5-7.8 of 78%, 74%, and 69%, respectively. Conclusions We found that there was a moderate correlation between HbA1c and TIR 3.5-7.8 during pregnancy. To achieve the HbA1c target <6.0%, pregnant women with type 1 diabetes should strive for TIR 3.5-7.8 >78% (18h 43min) during pregnancy.

scholarly journals Hybrid Closed-Loop Insulin Delivery Systems for People With Type 1 Diabetes

2021 ◽  
Vol 1 (6) ◽  
Author(s):  
Health Technology Assessment Team
Keyword(s):  
Type 1 Diabetes ◽  
Closed Loop ◽  
Glucose Monitoring ◽  
Glycemic Variability ◽  
Insulin Delivery ◽  
Monitoring Methods ◽  
Expert Review ◽  
Expert Review Panel ◽  
Time In Range

The CADTH Health Technology Expert Review Panel (HTERP) suggests that hybrid closed-loop insulin delivery (HCL) systems hold promise for the care of people with type 1 diabetes. HTERP considers that, at present, there are insufficient long-term data on clinically relevant and patient-important outcomes to recommend how extensive the role of HCL systems should be in care. HTERP recommends the collection of robust and comparative data for consideration of future reassessments that compare HCL systems to existing insulin delivery and glucose monitoring methods in terms of glycated hemoglobin (hemoglobin A1C); time-in-range; time above and below range; glycemic variability; quality of life; patient, parent or caregiver, and health care provider satisfaction; diabetes-related complications; discontinuation rates; and health system impact. Robust data are collected in well-designed comparative studies that are, among other considerations, of sufficient duration to ensure a clinically meaningful outcome assessment.

Glucose scan behaviour in people with type 1 diabetes using flash glucose monitoring in a real-world setting

2020 ◽  
Author(s):  
Daniel Hochfellner ◽  
Haris Ziko ◽  
Hesham Elsayed ◽  
Monika Cigler ◽  
Lisa Knoll ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Real World ◽  
Glucose Monitoring ◽  
Flash Glucose Monitoring ◽  
Real World Setting

Increased Time-in-Range with Sotagliflozin as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes as Demonstrated by 24-Week Continuous Glucose Monitoring (inTandem1, inTandem2)

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1179-P ◽  
Author(s):  
THOMAS DANNE ◽  
BERTRAND CARIOU ◽  
JOHN B. BUSE ◽  
SATISH K. GARG ◽  
JULIO ROSENSTOCK ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Adjunct Therapy ◽  
Time In Range
Sign in / Sign up

Export Citation Format

Share Document